Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Royalty Pharma plc (NASDAQ:RPRX) has received a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $42.00.

Several research firms have recently weighed in on RPRX. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. Morgan Stanley raised their price target on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Finally, The Goldman Sachs Group lifted their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th.

Hedge Funds Weigh In On Royalty Pharma

A number of large investors have recently modified their holdings of RPRX. Swedbank AB bought a new position in Royalty Pharma during the first quarter valued at approximately $251,461,000. New South Capital Management Inc. bought a new position in shares of Royalty Pharma during the 1st quarter valued at $44,384,000. ADAR1 Capital Management LLC purchased a new position in Royalty Pharma in the 4th quarter worth $37,130,000. Patient Capital Management LLC bought a new stake in Royalty Pharma in the fourth quarter worth $35,247,000. Finally, Homestead Advisers Corp boosted its position in Royalty Pharma by 40.7% during the first quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock valued at $57,502,000 after buying an additional 547,000 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Down 0.8 %

Shares of NASDAQ RPRX opened at $27.36 on Friday. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The company has a market cap of $16.24 billion, a P/E ratio of 20.42, a P/E/G ratio of 4.17 and a beta of 0.46. Royalty Pharma has a 52 week low of $25.20 and a 52 week high of $31.66. The business has a 50-day simple moving average of $27.93 and a two-hundred day simple moving average of $27.81.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The company had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. During the same quarter in the previous year, the company earned $0.85 earnings per share. Research analysts anticipate that Royalty Pharma will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is currently 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.